التفاصيل البيبلوغرافية
| العنوان: |
Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada. |
| المؤلفون: |
Judd, Sandra, Revon‐Riviere, Gabriel, Grover, Stephanie A., Deyell, Rebecca J., Vanan, Magimairajan Issai, Lewis, Victor A., Pecheux, Lucie, Zorzi, Alexandra P., Goudie, Catherine, Santiago, Raoul, Tran, Thai Hoa, Abbott, Lesleigh S., Brossard, Josee, Moorehead, Paul, Alvi, Saima, Portwine, Carol, Denburg, Avram, Whitlock, James A., Cohen‐Gogo, Sarah, Morgenstern, Daniel A. |
| المصدر: |
Cancer Medicine; Feb2024, Vol. 13 Issue 3, p1-11, 11p |
| مصطلحات موضوعية: |
PEDIATRIC oncology, PEDIATRIC therapy, IMMUNE checkpoint inhibitors, CANCER chemotherapy, MITOGEN-activated protein kinases, NEUROFIBROMA, CENTRAL nervous system tumors |
| مصطلحات جغرافية: |
CANADA |
| مستخلص: |
Background: The need for new therapies to improve survival and outcomes in pediatric oncology along with the lack of approval and accessible clinical trials has led to "out‐of‐trial" use of innovative therapies. We conducted a retrospective analysis of requests for innovative anticancer therapy in Canadian pediatric oncology tertiary centers for patients less than 30 years old between 2013 and 2020. Methods: Innovative therapies were defined as cancer‐directed drugs used (a) off‐label, (b) unlicensed drugs being used outside the context of a clinical trial, or (c) approved drugs with limited evidence in pediatrics. We excluded cytotoxic chemotherapy, cellular products, and cytokines. Results: We retrieved data on 352 innovative therapy drug requests. Underlying diagnosis was primary CNS tumor 31%; extracranial solid tumor 37%, leukemia/lymphoma 22%, LCH 2%, and plexiform neurofibroma 6%. RAS/MAP kinase pathway inhibitors were the most frequently requested innovative therapies in 28% of all requests followed by multi‐targeted tyrosine kinase inhibitors (17%), inhibitors of the PIK3CA‐mTOR‐AKT pathway (8%), immune checkpoints inhibitors (8%), and antibody drug conjugates (8%). In 112 out of 352 requests, innovative therapies were used in combination with another anticancer agent. 48% of requests were motivated by the presence of an actionable molecular target. Compassionate access accounted for 52% of all requests while public insurance was used in 27%. Mechanisms of funding varied between provinces. Conclusion: This real‐world data collection illustrates an increasing use of "out‐of‐trial" innovative therapies in pediatric oncology. This new field of practice warrants further studies to understand the impact on patient trajectory and equity in access to innovative therapies. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Medicine is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder